Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic
Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic First-in-Class Cancer Therapeutic Targets the Liver X Receptor (LXR)-ApoE Pathway Identified Using Rgenix’s Discovery Platform NEW YORK CITY, N.Y., January 6, 2017 – Rgenix, Inc.,
Comments